You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 31, 2024

Vietnam Issues First National Technical Regulation for Health Supplements

Subscribe to Updates

On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025.

Contents of Circular 12

The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements.

Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation.

Transitional Provisions

Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning.

Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission.

From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

April 30, 2011
Recent years have witnessed a proliferation in the number of products available under the “nutritional food” heading. For companies to stand out from their competitors in this growing sector, marketing and advertising is integral for success. The ability to make claims regarding products is a significant aspect of this process. While the number of products has been on the rise, there has also been an augmentation in demand among consumers for healthier, more nutritious products. This, coupled with more aggressive advertising tactics, could lead to exaggerated or egregious claims.
Read More
April 30, 2011
As most ASEAN Food and Drug Administrations and Ministries of Agriculture labor under critical backlogs of product registration applications for the growing number of products being released into Asian markets, businesses are looking to new ways to facilitate approvals. Outsourcing product registration work to law firms is becoming an increasingly popular way for regulatory affairs departments to speed up applications as local knowledge and effective navigation go a long way in Asia.
Read More
April 30, 2011
Recent scandals, particularly the one involving melamine-tainted milk from China, have impacted consumer awareness in a big way, making consumers pay more attention to the quality and safety of the products they purchase. This is particularly true for products that are ingested, such as food and beverages. In Thailand, these products must first receive approval from the Food and Drug Administration in the case of food and drugs, and the Excise Department in the case of alcoholic beverages, before launching in the market.
Read More
April 30, 2011
Recently, the members of Association of Southeast Asian Nations (ASEAN) attempted to improve product registration efficiency and marketing approval for pharmaceutical products. The ASEAN harmonization regime hopes to improve the standard of the Food and Drug Administrations’ (FDAs) regulatory reviews in ASEAN countries. Despite these efforts, however, the lingering obstacle of a lack of intellectual property understanding continues to leave pharmaceutical companies with difficulties when dealing with product registration in several ASEAN FDAs.
Read More